Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous- as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
| # | Name | Date |
|---|---|---|
| 1 | 202547007678-STATEMENT OF UNDERTAKING (FORM 3) [30-01-2025(online)].pdf | 2025-01-30 |
| 3 | 202547007678-Sequence Listing in PDF [30-01-2025(online)].pdf | 2025-01-30 |
| 4 | 202547007678-PRIORITY DOCUMENTS [30-01-2025(online)].pdf | 2025-01-30 |
| 5 | 202547007678-POWER OF AUTHORITY [30-01-2025(online)].pdf | 2025-01-30 |
| 6 | 202547007678-FORM 18 [30-01-2025(online)].pdf | 2025-01-30 |
| 7 | 202547007678-FORM 1 [30-01-2025(online)].pdf | 2025-01-30 |
| 8 | 202547007678-DRAWINGS [30-01-2025(online)].pdf | 2025-01-30 |
| 9 | 202547007678-DECLARATION OF INVENTORSHIP (FORM 5) [30-01-2025(online)].pdf | 2025-01-30 |
| 10 | 202547007678-COMPLETE SPECIFICATION [30-01-2025(online)].pdf | 2025-01-30 |
| 11 | 202547007678-Proof of Right [24-07-2025(online)].pdf | 2025-07-24 |
| 12 | 202547007678-FORM 3 [24-07-2025(online)].pdf | 2025-07-24 |